Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: European Surgery 1/2013

01.02.2013 | Original Article

The minimal dose of FK506 is sufficient to facilitate the arterialisation of venous allografts in rats

verfasst von: MD M. Varga, I. Matia, A. Lodererova, M. Adamec

Erschienen in: European Surgery | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

We investigated whether a minimal dose of FK506 is sufficient to inhibit the rejection of venous allografts and facilitate allograft adaptation to arterialisation in rats.

Methods

Iliolumbar veins from Brown Norway (BN) rats were transplanted into the abdominal aorta of Lewis (LEW) rats. Recipient animals received daily intramuscular injections of 0.1 mg kg 1 FK506. Light microscope evaluations of grafts were performed 30 days after transplantation. We investigated the presence of endothelial cells, the intensity of intimal proliferation, the deposition of immunoglobulin G molecules into the medial layer and the degree of adventitial infiltration by Lewis MHC class II-positive, CD4-positive and CD8-positive cells. All results were compared to previously reported data for syngeneic, allogeneic non-immunosuppressed and allogeneic FK506-low-dose immunosuppressed animals.

Results

All alloveins under minimal FK506 immunosuppression showed typical histological signs of arterialisation 30 days after transplantation. Intimal thickness (15.1 ± 6.1 mm) and the degree of adventitial infiltration by MHC class II-positive (16.96 ± 10.46), CD8-positive (2.63 ± 2.6), and CD4-positive (7.67 ± 8.29) cells were not significantly different when compared to untreated syngeneic veins and allogeneic veins treated with a low dose of FK506, respectively.

Conclusions

Even the minimal dose of FK506 was sufficient to inhibit the acute rejection of venous allografts and to facilitate allograft arterialisation 30 days after transplantation.
Literatur
1.
Zurück zum Zitat Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Eur J Vasc Endovasc Surg. 2000;19 Suppl A:Si-xxviii, S1–250. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Eur J Vasc Endovasc Surg. 2000;19 Suppl A:Si-xxviii, S1–250.
2.
Zurück zum Zitat Randon C, Jacobs B, De Ryck F, Beele H, Vermassen F. Fifteen years of infrapopliteal arterial reconstructions with cryopreserved venous allografts for limb salvage. J Vasc Surg. 2010;51(4):869–77. PubMedCrossRef Randon C, Jacobs B, De Ryck F, Beele H, Vermassen F. Fifteen years of infrapopliteal arterial reconstructions with cryopreserved venous allografts for limb salvage. J Vasc Surg. 2010;51(4):869–77. PubMedCrossRef
3.
Zurück zum Zitat Matia I, Janousek L, Marada T, Adamec M. Cold-stored venous allografts in the treatment of critical limb ischaemia. Eur J Vasc Endovasc Surg. 2007;34(4):424–31. PubMedCrossRef Matia I, Janousek L, Marada T, Adamec M. Cold-stored venous allografts in the treatment of critical limb ischaemia. Eur J Vasc Endovasc Surg. 2007;34(4):424–31. PubMedCrossRef
4.
Zurück zum Zitat Brockbank KG, McNally RT, Walsh KA. Cryopreserved vein transplantation. J Card Surg. 1992;7(2):170–6. PubMedCrossRef Brockbank KG, McNally RT, Walsh KA. Cryopreserved vein transplantation. J Card Surg. 1992;7(2):170–6. PubMedCrossRef
5.
Zurück zum Zitat Posner MP, Makhoul RG, Altman M, Kimball P, Cohen N, Sobel M, et al. Early results of infrageniculate arterial reconstruction using cryopreserved homograft saphenous conduit (CADVEIN) and combination low-dose systemic immunosuppression. J Am Coll Surg. 1996;183(3):208–16. PubMed Posner MP, Makhoul RG, Altman M, Kimball P, Cohen N, Sobel M, et al. Early results of infrageniculate arterial reconstruction using cryopreserved homograft saphenous conduit (CADVEIN) and combination low-dose systemic immunosuppression. J Am Coll Surg. 1996;183(3):208–16. PubMed
6.
Zurück zum Zitat Matia I, Lodererova A, Adamec M. Delayed administration of FK 506 is sufficient to suppress acute rejection changes after aortal transplantation in rats. Transpl Int. 2007;20(4):371–80. PubMedCrossRef Matia I, Lodererova A, Adamec M. Delayed administration of FK 506 is sufficient to suppress acute rejection changes after aortal transplantation in rats. Transpl Int. 2007;20(4):371–80. PubMedCrossRef
7.
Zurück zum Zitat Matia I, Varga M, Lodererova A, Adamec M. The positive effect of immunosuppression on adaptation of venous allografts to arterialisation in rats. Eur J Vasc Endovasc Surg. 2010;39(4):478–84. PubMedCrossRef Matia I, Varga M, Lodererova A, Adamec M. The positive effect of immunosuppression on adaptation of venous allografts to arterialisation in rats. Eur J Vasc Endovasc Surg. 2010;39(4):478–84. PubMedCrossRef
8.
Zurück zum Zitat Azuma N, Sasajima T, Kubo Y. Immunosuppression with FK506 in rat arterial allografts: fate of allogeneic endothelial cells. J Vasc Surg. 1999;29(4):694–702. PubMedCrossRef Azuma N, Sasajima T, Kubo Y. Immunosuppression with FK506 in rat arterial allografts: fate of allogeneic endothelial cells. J Vasc Surg. 1999;29(4):694–702. PubMedCrossRef
9.
Zurück zum Zitat Kwei S, Stavrakis G, Takahas M, Taylor G, Folkman MJ, Gimbrone MA Jr, et al. Early adaptive responses of the vascular wall during venous arterialization in mice. Am J Pathol. 2004;164(1):81–9. PubMedCrossRef Kwei S, Stavrakis G, Takahas M, Taylor G, Folkman MJ, Gimbrone MA Jr, et al. Early adaptive responses of the vascular wall during venous arterialization in mice. Am J Pathol. 2004;164(1):81–9. PubMedCrossRef
10.
Zurück zum Zitat Westerband A, Crouse D, Richter LC, Aguirre ML, Wixon CC, James DC, et al. Vein adaptation to arterialization in an experimental model. J Vasc Surg. 2001;33(3):561–9. PubMedCrossRef Westerband A, Crouse D, Richter LC, Aguirre ML, Wixon CC, James DC, et al. Vein adaptation to arterialization in an experimental model. J Vasc Surg. 2001;33(3):561–9. PubMedCrossRef
11.
Zurück zum Zitat Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330(20):1431–8. PubMedCrossRef Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330(20):1431–8. PubMedCrossRef
12.
Zurück zum Zitat Axthelm SC, Porter JM, Strickland S, Baur GM. Antigenicity of venous allografts. Ann Surg. 1979;189(3):290–3. PubMedCrossRef Axthelm SC, Porter JM, Strickland S, Baur GM. Antigenicity of venous allografts. Ann Surg. 1979;189(3):290–3. PubMedCrossRef
13.
Zurück zum Zitat Wagner E, Roy R, Marois Y, Douville Y, Guidoin R. Posttransplant antibodies and fresh venous allograft failure in dogs. Transplantation. 1994;58(5):537–42. PubMedCrossRef Wagner E, Roy R, Marois Y, Douville Y, Guidoin R. Posttransplant antibodies and fresh venous allograft failure in dogs. Transplantation. 1994;58(5):537–42. PubMedCrossRef
14.
Zurück zum Zitat Stevens SL, Tyler JD, Freeman MB, Hopkins F, Lewis T, Bray J, et al. Factors affecting patency of venous allografts in miniature swine. J Vasc Surg. 1990;12(3):361–6. PubMed Stevens SL, Tyler JD, Freeman MB, Hopkins F, Lewis T, Bray J, et al. Factors affecting patency of venous allografts in miniature swine. J Vasc Surg. 1990;12(3):361–6. PubMed
15.
Zurück zum Zitat Wagner E, Roy R, Marois Y, Douville Y, Guidoin R. Fresh venous allografts in peripheral arterial reconstruction in dogs. Effects of histocompatibility and of short-term immunosuppression with cyclosporine A and mycophenolate mofetil. J Thorac Cardiovasc Surg. 1995;110(6):1732–44. PubMedCrossRef Wagner E, Roy R, Marois Y, Douville Y, Guidoin R. Fresh venous allografts in peripheral arterial reconstruction in dogs. Effects of histocompatibility and of short-term immunosuppression with cyclosporine A and mycophenolate mofetil. J Thorac Cardiovasc Surg. 1995;110(6):1732–44. PubMedCrossRef
16.
Zurück zum Zitat Carpenter EW, Lindenauer SM. Immunosuppression in arterial and venous allografts. Arch Surg. 1973;106(1):77–8. PubMedCrossRef Carpenter EW, Lindenauer SM. Immunosuppression in arterial and venous allografts. Arch Surg. 1973;106(1):77–8. PubMedCrossRef
17.
Zurück zum Zitat Mingoli A, Edwards JD, Feldhaus RJ, Hunter WJ 3rd, Naspetti R, Cavallari N, et al. Fresh vein allograft survival in dogs after cyclosporine treatment. J Surg Res. 1996;62(1):95–102. PubMedCrossRef Mingoli A, Edwards JD, Feldhaus RJ, Hunter WJ 3rd, Naspetti R, Cavallari N, et al. Fresh vein allograft survival in dogs after cyclosporine treatment. J Surg Res. 1996;62(1):95–102. PubMedCrossRef
18.
Zurück zum Zitat Perloff LJ, Reckard CR, Rowlands DT Jr, Barker CF. The venous homograft: an immunological question. Surgery. 1972;72(6):961–70. PubMed Perloff LJ, Reckard CR, Rowlands DT Jr, Barker CF. The venous homograft: an immunological question. Surgery. 1972;72(6):961–70. PubMed
19.
Zurück zum Zitat Vermassen F, Degrieck N, De Kock L, Goubeau J, Van Landuyt K, Noens L, et al. Immunosuppressive treatment of venous allografts. Eur J Vasc Surg. 1991;5(6):669–75. PubMedCrossRef Vermassen F, Degrieck N, De Kock L, Goubeau J, Van Landuyt K, Noens L, et al. Immunosuppressive treatment of venous allografts. Eur J Vasc Surg. 1991;5(6):669–75. PubMedCrossRef
20.
Zurück zum Zitat Ricotta JJ, Collins GJ Jr, Rich NM, Reynolds DG. Failure of immunosuppression to prolong venous allograft survival. Arch Surg. 1980;115(1):99–101. PubMedCrossRef Ricotta JJ, Collins GJ Jr, Rich NM, Reynolds DG. Failure of immunosuppression to prolong venous allograft survival. Arch Surg. 1980;115(1):99–101. PubMedCrossRef
21.
Zurück zum Zitat Bandlien KO, Toledo-Pereyra LH, MacKenzie GH, Choudhury SP, Cortez JA. Immunosuppression with cyclosporine. A new approach to improve patency of venous allografts. Arch Surg. 1983;118(7):829–33. PubMedCrossRef Bandlien KO, Toledo-Pereyra LH, MacKenzie GH, Choudhury SP, Cortez JA. Immunosuppression with cyclosporine. A new approach to improve patency of venous allografts. Arch Surg. 1983;118(7):829–33. PubMedCrossRef
22.
Zurück zum Zitat Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab Invest. 1986;55(4):455–62. PubMed Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab Invest. 1986;55(4):455–62. PubMed
23.
Zurück zum Zitat Khanna A, Kapur S, Sharma V, Li B, Suthanthiran M. In vivo hyperexpression of transforming growth factor-beta1 in mice: stimulation by cyclosporine. Transplantation. 1997;63(7):1037–9. PubMedCrossRef Khanna A, Kapur S, Sharma V, Li B, Suthanthiran M. In vivo hyperexpression of transforming growth factor-beta1 in mice: stimulation by cyclosporine. Transplantation. 1997;63(7):1037–9. PubMedCrossRef
24.
Zurück zum Zitat Miller VM, Bergman RT, Gloviczki P, Brockbank KG. Cryopreserved venous allografts: effects of immunosuppression and antiplatelet therapy on patency and function. J Vasc Surg. 1993;18(2):216–26. PubMedCrossRef Miller VM, Bergman RT, Gloviczki P, Brockbank KG. Cryopreserved venous allografts: effects of immunosuppression and antiplatelet therapy on patency and function. J Vasc Surg. 1993;18(2):216–26. PubMedCrossRef
25.
Zurück zum Zitat Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002;73(5):775–82. PubMedCrossRef Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002;73(5):775–82. PubMedCrossRef
Metadaten
Titel
The minimal dose of FK506 is sufficient to facilitate the arterialisation of venous allografts in rats
verfasst von
MD M. Varga
I. Matia
A. Lodererova
M. Adamec
Publikationsdatum
01.02.2013
Verlag
Springer Vienna
Erschienen in
European Surgery / Ausgabe 1/2013
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI
https://doi.org/10.1007/s10353-012-0179-3